-
EP3955923
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3955923
| EP3955923 - COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 19.01.2024 Database last updated on 24.08.2024 | |
| Former | Examination is in progress Status updated on 01.09.2023 | ||
| Former | Request for examination was made Status updated on 21.01.2022 | ||
| Former | The international publication has been made Status updated on 23.10.2020 | ||
| Former | unknown Status updated on 18.05.2020 | Most recent event Tooltip | 19.01.2024 | Withdrawal of application | published on 21.02.2024 [2024/08] | Applicant(s) | For all designated states The Regents Of The University Of Michigan Office Of Technology Transfer 1600 Huron Parkway, 2nd Floor Ann Arbor, MI 48109-2590 / US | [2022/08] | Inventor(s) | 01 /
WHITEHEAD, Christopher E. c/o The Regents of the University of Michigan 1600 Huron Parkway, 2nd Floor Ann Arbor, Michigan 48109-2590 / US | 02 /
LEOPOLD, Judith S. c/o The Regents of the University of Michigan 1600 Huron Parkway, 2nd Floor Ann Arbor, Michigan 48109-2590 / US | 03 /
ZIEMKE, Elizabeth c/o The Regents of the University of Michigan 1600 Huron Parkway, 2nd Floor Ann Arbor, Michigan 48109-2590 / US | [2022/08] | Representative(s) | Algemeen Octrooi- en Merkenbureau B.V. P.O. Box 645 5600 AP Eindhoven / NL | [2022/08] | Application number, filing date | 20724683.6 | 18.04.2020 | [2022/08] | WO2020US28882 | Priority number, date | US201962835903P | 18.04.2019 Original published format: US 201962835903 P | [2022/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020215037 | Date: | 22.10.2020 | Language: | EN | [2020/43] | Type: | A1 Application with search report | No.: | EP3955923 | Date: | 23.02.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.10.2020 takes the place of the publication of the European patent application. | [2022/08] | Search report(s) | International search report - published on: | EP | 22.10.2020 | Classification | IPC: | A61K31/437, A61K31/4706, A61K31/4709, A61K31/506, A61K31/517, A61K31/5377, A61K45/06, A61P35/00, A61P35/04, A61K38/00 | [2022/08] | CPC: |
A61K45/06 (EP);
A61K31/517 (EP,US);
A61K31/437 (EP);
A61K31/4706 (EP);
A61K31/4709 (EP);
A61K31/506 (EP);
A61K31/5377 (EP);
A61K39/3955 (EP,US);
A61P35/00 (EP,US);
| C-Set: |
A61K31/437, A61K2300/00 (EP);
A61K31/4706, A61K2300/00 (EP);
A61K31/4709, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/517, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/08] | Title | German: | KOMBINATION MIT CHECKPOINT-INHIBITOREN ZUR BEHANDLUNG VON KREBS | [2022/08] | English: | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | [2022/08] | French: | COMBINAISON D'INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER | [2022/08] | Entry into regional phase | 26.10.2021 | National basic fee paid | 26.10.2021 | Designation fee(s) paid | 26.10.2021 | Examination fee paid | Examination procedure | 26.10.2021 | Examination requested [2022/08] | 26.10.2021 | Date on which the examining division has become responsible | 23.05.2022 | Amendment by applicant (claims and/or description) | 31.08.2023 | Despatch of a communication from the examining division (Time limit: M06) | 18.01.2024 | Application withdrawn by applicant [2024/08] | Fees paid | Renewal fee | 20.04.2022 | Renewal fee patent year 03 | 16.03.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YD]WO2015069770 (COGNATE BIOSERVICES INC [US], et al) [YD] 1-56 * claims 1-5,10-12 * * examples 1-5 * * paragraph [0095] *; | [Y]WO2018085674 (UNIV MICHIGAN REGENTS [US]) [Y] 1-56 * claims 1,9 * * examples * * page 1, lines 27-33 * * compound MTX-211; page 45 *; | [A]WO2018181542 (TERUMO CORP [JP]) [A] 1-56 * claims 1-3 ** paragraphs [0014] , [0245] - [0248] * | by applicant | US150 | US6265 | US3989816 | US4369174 | US4444762 | US4842866 | WO9306213 | US5217720 | US5565332 | US5580717 | US5733743 | US6569457 | US6638534 | US7314622 | US8008449 | WO2015069770 | - BUCK E et al., Mol Cancer Ther., (20060000), vol. 5, pages 2676 - 2684 | - N Engl J Med, (20150000), vol. 372, pages 2006 - 2017 | - CHOTHIA, C.LESK, A.M., J. Mol. Biol., (19870000), vol. 196, pages 901 - 917 | - MARTIN ACR et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 9268 - 72 | - MARTIN ACR et al., Methods Enzymol., (19910000), vol. 203, pages 121 - 153 | - PEDERSEN JT et al., Immunomethods, (19920000), vol. 1, pages 126 - 136 | - LEACH, Science, (19960000), vol. 271, pages 1734 - 1736 | - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546 | - TRIEBEL et al., J. Exp. Med., (19900000), vol. 171, pages 1393 - 1405 | - Murata, Am. J. Pathol., (19990000), vol. 155, pages 453 - 460 | - BALZANO, Int. J. Cancer Suppl., (19920000), vol. 7, pages 28 - 32 | - "GenBank", Database accession no. U64863 | - FREIREICH et al., Cancer Chemother. Rep., (19660000), vol. 50, page 219 | - Scientific Tables, Geigy Pharmaceuticals, (19700000), vol. 537 | - MARK et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 3242 | - FAN QW et al., Cancer Res., (20070000), vol. 67, pages 7960 - 7965 | - HAMADA K et al., Genes Dev, (20050000), vol. 19, no. 17, pages 2054 - 65 | - ATREYA CESANGALE ZXU N et al., Cancer Med., (20130000), vol. 2, pages 496 - 506 | - SAWAI H et al., BMC Gastroenterol., (20080000), vol. 8, page 56 | - BETHUNE G et al., J Thorac Dis., (20100000), vol. 2, pages 48 - 51 | - SPANO JP et al., Ann Oncol., (20050000), vol. 16, pages 189 - 194 | - HEIMBERGER AB et al., J Transl Med., (20050000), vol. 3, page 38 | - PSYRRI A et al., Am Soc Clin Oncol Educ Book., (20130000), pages 246 - 255 | - LUI VW et al., Cancer Discov., (20130000), vol. 3, pages 761 - 769 | - JIN G et al., Lung Cancer, (20100000), vol. 69, pages 279 - 283 | - GADGEEL SM et al., Clin Lung Cancer, (20130000), vol. 14, pages 322 - 332 | - PARDOLL, Nature Reviews Cancer, (20120000), vol. 12, pages 252 - 264 | - OKAZAKI et al., Int Immunol., (20070000), vol. 19, pages 813 - 824 | - HIRANO, F. et al., Cancer Res., (20050000), vol. 65, no. 3, pages 1089 - 1096 | - LI, B. et al., Clin. Cancer Res., (20090000), vol. 15, pages 1507 - 1509 | - CURRAN, M. A. et al., Proc. Natl. Acad. Set, (20100000), vol. 107, no. 9, pages 4275 - 4280 | - SJOBLOM et al., Science, (20060000), vol. 314, pages 268 - 74 | - HODI et al., N Engl J Med, (20100000), vol. 363, pages 711 - 23 | - TOPALIAN et al., N Engl J Med, (20120000), vol. 366, pages 2443 - 54 | - TOPALIAN et al., Curr Opin Immunol, (20120000), vol. 24, pages 207 - 12 | - TOPALIAN et al., J Clin Oncol, (20140000), vol. 32, no. 10, pages 1020 - 30 | - HAMID et al., N Engl J Med, (20130000), vol. 369, pages 122 - 133 | - HAMIDCARVAJAL, Expert Opin Biol Ther, (20130000), vol. 13, no. 6, pages 847 - 61 | - MCDERMOTTATKINS, Cancer Med, (20130000), vol. 2, no. 5, pages 662 - 73 | - CHRISTIAN U. BLANKALEXANDER ENK, "Therapeutic use of anti-CTLA-4 antibodies", International Immunology, vol. 27, no. 1, doi:10.1093/intimm/dxu076, pages 3 - 10, XP055422940 DOI: http://dx.doi.org/10.1093/intimm/dxu076 | - CURRAN et al., "Combination of CTLA-4 and PD-1 blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", PNASI, (20100302), vol. 107, no. 9, doi:10.1073/pnas.0915174107, pages 4275 - 4280, XP055611670 DOI: http://dx.doi.org/10.1073/pnas.0915174107 | - Proc Natl Acad Sci USA, (20100000), vol. 107, pages 4275 - 4280 | - LUAN et al., "Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence", Blood, (20160000), vol. 128, no. 22, page 5983 | - ZERDES et al., "Genetic, transcriptional and posttranslational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations", Oncogene, (20180000), vol. 37, doi:10.1038/s41388-018-0303-3, pages 4639 - 4661, XP036572892 DOI: http://dx.doi.org/10.1038/s41388-018-0303-3 | - LEIBOWITZ et al., "Post-transcriptional regulation of immune checkpoint genes by mir-16 in melanoma", Annals of Oncology, (20170000), vol. 28, pages v428 - v448 | - BOLDINI et al., "Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma", Cancer Cell Int., (20170000), vol. 17, page 105 | - HOSSAIN et al., "The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy", Ther. Deliv., (20150100), vol. 6, no. 1, doi:10.4155/tde.14.92, pages 1 - 4, XP055556134 DOI: http://dx.doi.org/10.4155/tde.14.92 | - WATANABE et al., "Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity", J Clin Invest., (20170630), vol. 127, no. 7, pages 2725 - 2738 | - SHI et al., "Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints", Int J Mol Sci., (20180500), vol. 19, no. 5, page 1389 | - TRUITT et al., "New frontiers in translational control of the cancer genome", Nat Rev Cancer, (20160426), vol. 16, no. 5, pages 288 - 304 | - BRUNET et al., "A new member of the immunoglobulin superfamily--CTLA-4", Nature, (19870716), vol. 328, no. 6127, doi:10.1038/328267a0, pages 267 - 70, XP002915323 DOI: http://dx.doi.org/10.1038/328267a0 | - LINSLEY et al., "CTLA-4 is a second receptor for the B cell activation antigen B7", J Exp Med., (19910901), vol. 174, no. 3, doi:10.1084/jem.174.3.561, pages 561 - 9, XP000199778 DOI: http://dx.doi.org/10.1084/jem.174.3.561 | - CHAMBERS et al., "Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells", Immunity, (19971200), vol. 7, no. 6, pages 885 - 95 | - LUHDER, J. Exp. Med., (19980000), vol. 187, pages 427 - 432 | - WALUNAS et al., Immunity, (19940000), vol. 1, pages 405 - 413 | - KEARNEY, J. Immunol., (19950000), vol. 155, pages 1032 - 1036 | - CHAMBERS, Curr. Opin. Immunol., (19970000), vol. 9, pages 396 - 404 | - BLUESTONE, J. Immunol., (19970000), vol. 158, pages 1989 - 1993 | - THOMPSON, Immunity, (19970000), vol. 7, pages 445 - 450 | - ISHIDA, Y et al., EMBO J., (19920000), vol. 11, page 3887 | - KIER, MARY E et al., Annu Rev Immunol, (20080000), vol. 26, pages 677 - 704 | - OKAZAKI, TAKU et al., International Immunology, (20070000), vol. 19, pages 813 - 824 | - AGATA, Y et al., Int Immunol, (19960000), vol. 8, pages 765 - 72 | - FREEMAN, GORDON et al., J Exp Med, (20000000), vol. 192, page 1027 | - LATCHMAN, Y et al., Nat Immunol, (20010000), vol. 2, page 261 | - CHEMNITZ, J et al., J Immunol, (20040000), vol. 173, pages 945 - 954 | - RILEY, JAMES L, Immunological Reviews, (20090000), vol. 229, pages 114 - 125 | - FRANCISCO, LOISE M et al., J Exp Med, (20090000), vol. 206, pages 3015 - 3029 | - SANCHEZ-FUEYO et al., "Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance", Nat. Immunol., (20030000), vol. 4, doi:10.1038/ni987, pages 1093 - 1101, XP055247627 DOI: http://dx.doi.org/10.1038/ni987 | - KOGUCHI K et al., J Exp Med., (20060000), vol. 203, pages 1413 - 8 | - DEKRYFF et al., "T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells", J Immunol., (20100215), vol. 184, no. 4, doi:10.4049/jimmunol.0903059, pages 1918 - 30, XP055589342 DOI: http://dx.doi.org/10.4049/jimmunol.0903059 | - CHIBA et al., "Tumor- infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB 1", Nat Immunol., (20120900), vol. 13, no. 9, pages 832 - 42 | - HUANG et al., "CEACAM1 regulates TIM-3-mediated tolerance and exhaustion", Nature, (20150115), vol. 517, no. 7534, doi:10.1038/nature13848, pages 386 - 90, XP055285800 DOI: http://dx.doi.org/10.1038/nature13848 | - GONZALEZ et al., Proc. Natl. Acad. Sci. USA, (20050000), vol. 102, pages 1116 - 21 | - GAVRIELI et al., Bioochem. Biophysi Res Commun, (20030000), vol. 312, pages 1236 - 43 | - YOON et al., "Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53", Science, (20150731), vol. 349, no. 6247, page 1261669 | - WANG et al., "VSIG-3 as a ligand of VISTA inhibits human T-cell function", Immunology, (20190100), vol. 156, no. 1, pages 74 - 85, XP002796287 DOI: http://dx.doi.org/10.1111/imm.13001 | - HUARD et al., Immunogenetics, (19940000), vol. 39, page 213 | - HUANG, C. et al., Immunity, (20040000), vol. 21, pages 503 - 513 | - CAMISASCHI et al., J Immunol., (20100000), vol. 184, pages 6545 - 6551 | - GAGLIANI et al., Nat Med, (20130000), vol. 19, pages 739 - 746 | - WORKMAN et al., J Immunol, (20090000), vol. 182, pages 1885 - 1891 | - BAIXERAS et al., J. Exp. Med., (19920000), vol. 176, pages 327 - 337 | - HUARD et al., Eur. J. Immunol., (19960000), vol. 26, pages 1180 - 1186 | - HUARD et al., Eur. J. Immunol., (19940000), vol. 24, pages 3216 - 3221 | - GROSS et al., J Clin Invest., (20070000), vol. 117, pages 3383 - 3392 | - BLACKBURN et al., Nat. Immunol., (20090000), vol. 10, pages 29 - 37 | - IOUZALEN et al., Eur. J. Immunol., (20010000), vol. 31, pages 2885 - 2891 | - WORKMAN, C. J.VIGNALI, D. A., J. Immunol., (20050000), vol. 174, pages 688 - 695 | - HUARD et al., "CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins", Eur J Immunol., (19950900), vol. 25, no. 9, pages 2718 - 21, XP000672291 | - MARIN-ACEVEDO et al., "Next generation of immune checkpoint therapy in cancer: new developments and challenges", J Hematol Oncol., (20180000), vol. 11, doi:10.1186/s13045-018-0582-8, page 39, XP055642850 DOI: http://dx.doi.org/10.1186/s13045-018-0582-8 | - KOHLER, B.MILSTEIN, C., Nature, (19750000), vol. 256, pages 495 - 497 | - WINTER et al., Annu. Rev. Immunol., (19940000), vol. 12, pages 433 - 455 | - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 553 | - GRIFFITH et al., EMBO J., (19930000), vol. 12, pages 725 - 734 | - MARKS et al., Bio/Technol., (19920000), vol. 10, pages 779 - 783 | - WATERHOUSE et al., Nucl. Acids Res., (19930000), vol. 21, pages 2265 - 2266 | - TILLER et al., J. Immunol. Methods, (20080000), vol. 329, page 112 | - HAYHURSTGEORGIOU, Curr. Opin. Chem. Biol., (20010000), vol. 5, pages 683 - 689 | - MAYNARDGEORGIOU, Annu. Rev. Biomed. Eng., (20000000), vol. 2, pages 339 - 76 | - MORRISON, S., Science, (19850000), vol. 228, page 1202 | - PEETERS et al., Vaccine, (20010000), vol. 19, page 2756 | - LONBERG, N.D. HUSZAR, Int. Rev. Immunol, (19950000), vol. 13, page 65 | - HORWITZ, A. H. et al., Proc. Natl. Acad. Sci., vol. 85, pages 8678 - 8682 | - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783 | - BARBAS et al., Proc Nat. Acad. Sci. USA, (19940000), vol. 91, pages 3809 - 3813 | - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507 | - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533 | - TREAT et al., LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE AND CANCER, (19890000), pages 353 - 365 | - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201 | - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574 | - RANGERPEPPAS, J. Macromol. Sci. Rev. Macromol. Chem., (19830000), vol. 23, page 61 | - DURING et al., Ann. Neurol., (19890000), vol. 25, page 351 | - HOWARD et al., J. Neurosurg., (19890000), vol. 71, page 105 | - GIBNEY et al., "Predictive biomarkers for checkpoint inhibitor-based immunotherapy", Lancet Oncol., (20161200), vol. 17, no. 12, pages e542 - e551 | - UTE F. ROHRIG, JMC, (20120000), vol. 55, no. 11, pages 5270 - 5290 | - PEDOEEM, A. et al., "Programmed death-1 pathway in cancer and autoimmunity", Clinical Immunology, (20140000), vol. 153, no. 1, doi:10.1016/j.clim.2014.04.010, pages 145 - 152, XP029006146 DOI: http://dx.doi.org/10.1016/j.clim.2014.04.010 | - FRANCISCO, L.M. et al., "The PD-1 pathway in tolerance and autoimmunity", Immunological Reviews, (20100000), vol. 236, doi:10.1111/j.1600-065X.2010.00923.x, pages 219 - 42, XP002616816 DOI: http://dx.doi.org/10.1111/j.1600-065X.2010.00923.x | - YOKOSUKA, T. et al., "Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2", The Journal of Experimental Medicine, (20120000), vol. 209, no. 6, doi:10.1084/jem.20112741, pages 1201 - 1217, XP002753472 DOI: http://dx.doi.org/10.1084/jem.20112741 | - LASTWIKA, K.J. et al., "Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer", Cancer Research, (20160000), vol. 76, no. 2, doi:10.1158/0008-5472.CAN-14-3362, pages 227 - 238, XP055600222 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-14-3362 | - MASCIA F. et al., "Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas", International Journal of Cancer, (20160000), vol. 139, no. 11, pages 2593 - 7 | - LI C. et al., "Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity", Nature Communications, (20160000), vol. 7, doi:10.1038/ncomms12632, page 12632, XP055371693 DOI: http://dx.doi.org/10.1038/ncomms12632 |